首页> 美国卫生研究院文献>Drug Design Development and Therapy >Long-Term Safety of a Novel Angiotensin Receptor Blocker Fimasartan According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective 12-Month Observational Study

【2h】

Long-Term Safety of a Novel Angiotensin Receptor Blocker Fimasartan According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective 12-Month Observational Study

机译：根据韩国高血压患者是否存在基础肝病新型血管紧张素受体阻滞剂Fimasartan的长期安全性：一项为期12个月的观察性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Fimasartan, the ninth and most recent angiotensin receptor blocker (ARB) approved by the Korea Food and Drug Administration, has shown similar efficacy and safety profiles compared to other ARBs. However, due to being predominantly excreted by the hepatobiliary system, concerns on safety have been raised regarding its use in patients with underlying liver disease.

机译：Fimasartan是韩国食品药品监督管理局批准的第九种也是最新的血管紧张素受体阻滞剂（ARB），与其他ARB相比，已显示出相似的功效和安全性。但是，由于主要由肝胆系统排泄，因此对于在潜在肝病患者中使用它的安全性引起了关注。

著录项

期刊名称 Drug Design Development and Therapy
作者
Gyu Chul Oh; Kwon Wook Joo; Myung-A Kim; Dong-Ju Choi; Yoon Jun Kim; Hae-Young Lee;
展开▼
作者单位

展开▼
年(卷),期 2020(14),-1
年度 2020
页码 -1
总页数 9
原文格式 PDF
正文语种
中图分类药学;药物化学;
关键词
fimasartan; safety; liver disease; essential hypertension; hepatobiliary excretion; adverse event;

机译：氟马沙坦;安全性;肝脏疾病;高血压;肝胆排泄;不良事件;

相似文献

外文文献
中文文献
专利

1. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study [J] . Gyu Chul Oh, Kwon Wook Joo, Myung-A Kim, Drug Design, Development and Therapy . 2020,第1期

机译：新型血管紧张素受体阻滞剂的长期安全性，Fimasartan根据韩国高血压患者的缺失或存在的缺失或存在：一个未来，12个月，观察研究
2. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): A 12-week, phase iii, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult korean patients with mild-to-moderate hypertension [J] . LeeS.E., KimY.-J., LeeH.-Y., Clinical therapeutics . 2012,第3期

机译：与氯沙坦（50/100 mg）相比，一种新的血管紧张素受体阻滞剂氟马沙坦的疗效和耐受性：一项为期12周的iii期，多中心，前瞻性，随机，双盲，平行组剂量递增临床试验，成年韩国轻度至中度高血压患者的可选12周延长期
3. A Pilot Study on the Effect of Angiotensin Receptor Blockers on Platelet Aggregation in Hypertensive Patients- A Prospective Observational Study [J] . Arun Suresh, Narendranath Sanji, Pallavi Mahadeva Kamath, Journal of Clinical and Diagnostic Research . 2016,第11期

机译：血管紧张素受体阻滞剂对高血压患者血小板聚集的影响的前瞻性观察研究
4. The Long-Term Clinical Results of a Platelet Glycoprotein Ilb/IIIa Receptor Blocker (Abciximab: ReoPro~R)-Coated Stent in Patients with Coronary Artery Disease [C] . W. Kim, M.H. Jeong, Y.J. Hong, International Congress on Thrombosis . 2004

机译：冠状动脉疾病患者的血小板糖蛋白ILB / IIIA受体阻滞剂（Abciximab：Reopro〜R）涂层支架的长期临床结果
5. A Pilot Study on the Effect of Angiotensin Receptor Blockers on Platelet Aggregation in Hypertensive Patients- A Prospective Observational Study [O] . Arun Suresh, Narendranath Sanji, Pallavi Mahadeva Kamath, 2016

机译：血管紧张素受体阻滞剂对高血压患者血小板聚集影响的前瞻性观察研究
6. >Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study [O] . Gyu Chul Oh, Kwon Wook Joo, Myung-A Kim, 2020

机译：>新型血管紧张素受体阻滞剂的长期安全性，Fimasartan根据韩国高血压患者的缺失或存在的潜在肝病：一个前瞻性，12个月，观察研究

Long-Term Safety of a Novel Angiotensin Receptor Blocker Fimasartan According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective 12-Month Observational Study

摘要

著录项

相似文献

相关主题

期刊订阅